Cotización Fortress Biotech - FBIO

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

1.57

Postura de Compra

1.55

Postura de Venta

1.70

Volume Operado de la Acción

0.00 Rango del Día 0.00

1.355 Rango de 52 semanas 4.43

Capitalización de Mercado [m]

43.34M

Precio Anterior

1.57

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

613,121

Acciones en circulación

27,604,934

Rendimiento del Dividendo

Ratio Precio/Utilidad

-0.63

Beneficio por acción (BPA)

-2.49

turnover

84.51M

Beneficio neto

-68.67M

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the g... Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.fortressbiotech.com

Sede

Dover, Delaware, USA

Fundado

Fortress Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FBIO. The last closing price for Fortress Biotech was US$1.57. Over the last year, Fortress Biotech shares have traded in a share price range of US$ 1.355 to US$ 4.43.

Fortress Biotech currently has 27,604,934 shares in issue. The market capitalisation of Fortress Biotech is US$43.34 million. Fortress Biotech has a price to earnings ratio (PE ratio) of -0.63.

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or...

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of...

Mustang Bio Receives Positive Listing Determination from Nasdaq

WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1...

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.065	-3.9755351682	1.635	1.635	1.41	494198	1.51268398	CS
4	-0.2	-11.2994350282	1.77	2.1	1.41	587824	1.7615855	CS
12	-0.48	-23.4146341463	2.05	2.1	1.355	613121	1.64697158	CS
26	-0.41	-20.7070707071	1.98	2.89	1.355	411847	1.75983971	CS
52	-1.26	-44.5229681979	2.83	4.43	1.355	422838	2.03872511	CS
156	-44.48	-96.5906623236	46.05	46.725	1.24	491850	10.34326612	CS
260	-26.18	-94.3423423423	27.75	91.5	1.24	656920	34.07592602	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	0
AACGATA Creativity Global	US$ 1.02 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	0
AACGATA Creativity Global	US$ 1.02 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	0
AACGATA Creativity Global	US$ 1.02 (0.00%)	0